-
Je něco špatně v tomto záznamu ?
Cisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy
V. Novohradsky, T. Babu, H. Kostrhunova, M. Plaskow, L. Markova, S. Acharya, D. Gibson, V. Brabec
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
- MeSH
- cisplatina * farmakologie MeSH
- eugenol * farmakologie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nádorové kmenové buňky * účinky léků patologie MeSH
- nádory tračníku * farmakoterapie patologie MeSH
- prekurzory léčiv * farmakologie chemie MeSH
- protinádorové látky * farmakologie chemie MeSH
- synergismus léků MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Platinum(IV) compounds possess distinct properties that set them apart from platinum(II) compounds. Often designed as prodrugs, they are reduced within cancer cells to their active platinum(II) form, enabling their cytotoxic effects. Their versatility also lies in their ability to be functionalized and conjugated with bioactive molecules to enhance cancer cell targeting. This report introduces new prodrugs that combine antitumor cisplatin with axially coordinated eugenol, leveraging their synergistic action to target cancer stem cells. A third bioactive ligand, 4-phenylbutyrate or octanoate, was added to further enhance biological activity, creating 'triple action' prodrugs. These new platinum(IV) prodrugs offer a novel approach to cancer therapy by improving targeting, increasing efficacy, overcoming drug resistance, and reducing tumor invasiveness while sparing healthy tissue.
Czech Academy of Sciences Institute of Biophysics Kralovopolska 135 Brno CZ 61200 Czech Republic
Institute for Drug Research School of Pharmacy The Hebrew University Jerusalem 91120 Israel
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25010024
- 003
- CZ-PrNML
- 005
- 20250429134851.0
- 007
- ta
- 008
- 250415e20250118fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2025.117854 $2 doi
- 035 __
- $a (PubMed)39827811
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Novohradsky, Vojtech $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno CZ-61200, Czech Republic
- 245 10
- $a Cisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy / $c V. Novohradsky, T. Babu, H. Kostrhunova, M. Plaskow, L. Markova, S. Acharya, D. Gibson, V. Brabec
- 520 9_
- $a Platinum(IV) compounds possess distinct properties that set them apart from platinum(II) compounds. Often designed as prodrugs, they are reduced within cancer cells to their active platinum(II) form, enabling their cytotoxic effects. Their versatility also lies in their ability to be functionalized and conjugated with bioactive molecules to enhance cancer cell targeting. This report introduces new prodrugs that combine antitumor cisplatin with axially coordinated eugenol, leveraging their synergistic action to target cancer stem cells. A third bioactive ligand, 4-phenylbutyrate or octanoate, was added to further enhance biological activity, creating 'triple action' prodrugs. These new platinum(IV) prodrugs offer a novel approach to cancer therapy by improving targeting, increasing efficacy, overcoming drug resistance, and reducing tumor invasiveness while sparing healthy tissue.
- 650 12
- $a cisplatina $x farmakologie $7 D002945
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a prekurzory léčiv $x farmakologie $x chemie $7 D011355
- 650 12
- $a nádorové kmenové buňky $x účinky léků $x patologie $7 D014411
- 650 12
- $a eugenol $x farmakologie $7 D005054
- 650 12
- $a nádory tračníku $x farmakoterapie $x patologie $7 D003110
- 650 12
- $a protinádorové látky $x farmakologie $x chemie $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a synergismus léků $7 D004357
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Babu, Tomer $u Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem 91120, Israel
- 700 1_
- $a Kostrhunova, Hana $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno CZ-61200, Czech Republic
- 700 1_
- $a Plaskow, Menucha $u Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem 91120, Israel
- 700 1_
- $a Markova, Lenka $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno CZ-61200, Czech Republic
- 700 1_
- $a Acharya, Sourav $u Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem 91120, Israel
- 700 1_
- $a Gibson, Dan $u Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem 91120, Israel. Electronic address: dang@ekmd.huji.ac.il
- 700 1_
- $a Brabec, Viktor $u Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, Brno CZ-61200, Czech Republic; Department of Biophysics, Faculty of Science, Palacky University, Slechtitelu 27, Olomouc 783 71, Czech Republic. Electronic address: vbrabec44@gmail.com
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 183 (20250118), s. 117854
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39827811 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134847 $b ABA008
- 999 __
- $a ok $b bmc $g 2311411 $s 1247105
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 183 $c - $d 117854 $e 20250118 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20250415
